Why not Bayer? They certainly would have the contacts and incentive to make it happen. It does make me a little suspicious why this not only didn't go up on the good news but went down. Possible but unlikely.
mean to say valuation is around 250 (leaving cash) after q1 burn. The drug could net $300m/year in the US alone. I don't get valuation is so low. Why wouldn't a big pharma acquirer make an offer at a premium say 40%